Ask about this productRelated genes to: PROCR antibody
- Gene:
- PROCR NIH gene
- Name:
- protein C receptor
- Previous symbol:
- -
- Synonyms:
- EPCR, CCD41, CD201
- Chromosome:
- 20q11.22
- Locus Type:
- gene with protein product
- Date approved:
- 2000-06-26
- Date modifiied:
- 2019-04-23
Related products to: PROCR antibody
Related articles to: PROCR antibody
- Definitive hematopoietic stem cells (HSCs) emerge within intra-aortic hematopoietic cell clusters (IAHCs) located in the dorsal aorta of the aorta-gonad-mesonephros (AGM) region during midgestation in the mouse embryo. Thereafter, HSCs migrate to the fetal liver (FL) and finally settle in the bone marrow (BM). We previously showed that the transcription factor Sox17 is expressed in IAHCs. Overexpression of the Sox17 gene in IAHC cells induces the formation of cell clusters in vitro that resemble IAHCs and retain hematopoietic potential. In addition, a previous report showed that Sox17-transduced hematopoietic stem/progenitor cells (HSPCs) in the BM maintained multipotency. However, whether the ability to form such cell clusters differs among hematopoietic sites has not been fully examined. - Source: PubMed
Publication date: 2026/04/23
Itabashi AyumiYokoi YukiSaito KiyokaTsukahara RyotaMelig GerelAzuma KoyaIizuka NaokiTaga TetsuyaNobuhisa Ikuo - Psoriasis is a T cell-mediated inflammatory skin disease, and biologics have demonstrated promising efficacy. However, some patients remain dissatisfied with early therapeutic outcomes. Immune checkpoint molecules on T cells play critical roles in psoriasis pathogenesis, yet their impact on therapeutic response remains unclear. This study aimed to identify predictive markers for the early therapeutic efficacy of ixekizumab in psoriasis patients. - Source: PubMed
Publication date: 2026/03/27
Yang NanChen ZeyuJiang YuxiongCai JiangluyiCui LianWang YuanyuanLin SuyangWu LingDu QianGu JunGong YuYu QianShi Yuling - Type 2 diabetes mellitus (T2DM) is a major health burden in Saudi Arabia. Its prevalence is estimated at 16.4% to 28% among adults. It is characterized by chronic hyperglycemia inducing low-grade inflammation, which drives various physiological changes, including endothelial dysfunction. The endothelial protein C receptor (EPCR) is a membrane-bound receptor expressed on normal endothelial cells and is released upon endothelial dysfunction into the blood as soluble EPCR (sEPCR). Increased cleavage and release of EPCR is associated with the EPCR rs867186 polymorphism. Therefore, the current study aimed to investigate the pattern and frequency of EPCR rs867186 polymorphism and plasma levels of sEPCR in patients with T2DM and healthy controls. - Source: PubMed
Publication date: 2026/03/23
Alattas NoranEssawi KhaledMobarki Abdullah ADobie GasimHakami WaleedMusawi ShaqraaAlhakami Fatemah AHabibullah Mahmoud MAlyahyawi YaraMadkhali Aymen MHamali Hassan A - The endothelial protein C receptor (EPCR) is an important component of the protein C (PC) system, recognised for its diverse roles in blood coagulation, inflammation, and stem cell regulation. Wound healing is a complex physiological process that can be divided into four distinct but overlapping phases: haemostasis, inflammation, proliferation and remodelling. Recently, EPCR has emerged as a key regulator in wound repair and regeneration. During haemostasis, EPCR enhances the conversion of PC to its activated form (APC) to optimise local and systemic anticoagulation. In the inflammatory phase, EPCR modulates immune cell activity, inhibits inflammatory factors, and maintains tissue barrier integrity. As the process transitions to the proliferative phase, EPCR promotes endothelial and epithelial cell proliferation, migration, neovascularisation and re-epithelization, and mediates the expression of matrix metalloproteinases to facilitate tissue reconstruction. Finally, during the remodelling phase, EPCR exerts a potential antifibrotic effect by regulating fibroblast activation and collagen deposition via the Transforming growth factor (TGF)-β1/Smad3 pathway, ensuring functional repair. While therapeutic potential has been shown in animal models, translating EPCR-mediated therapies to clinical application faces many challenges, including wound heterogeneity, dosage control, targeted delivery, and potential bleeding risks. Studies have shown that local drug delivery strategies, non-anticoagulant APC variants, and individualised treatment based on EPCR expression will be the key directions for future development. Additionally, EPCR may serve as a potential biomarker for assessing wound severity and guiding personalised interventions. - Source: PubMed
Publication date: 2026/03/22
Wang HuiMarch LynJackson Christopher JCross MaritaXue Meilang - Primary Antiphospholipid Syndrome (PAPS) is a systemic autoimmune disorder characterized by arterial and/or venous thrombosis and obstetric morbidity. Arterial thrombosis, although less frequent than venous events, is associated with substantial morbidity and mortality. Alongside environmental and acquired factors, several genetic polymorphisms affecting coagulation, endothelial function, fibrinolysis, and platelet activation have been investigated in relation to thrombotic risk. Clarifying their contribution may help refine hypotheses for risk stratification. - Source: PubMed
Publication date: 2026/03/05
Gavris ClaudiaSovaila SilviaGirdan LauraPurcarea Adrian